Access Bio, Inc. (KOSDAQ:950130)
South Korea · Delayed Price · Currency is KRW 3,415.00
-70.00 (-2.01%)
Apr 30, 2026, 3:30 PM KST
Access Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | - | - | - | 0 |
| 31,255 | 112,463 | 348,643 | 1,033,863 | 505,112 | |
Revenue Growth (YoY) | -72.21% | -67.74% | -66.28% | 104.68% | 314.71% |
Cost of Revenue | 56,022 | 59,197 | 178,765 | 214,488 | 109,147 |
Gross Profit | -24,767 | 53,266 | 169,878 | 819,375 | 395,965 |
Selling, General & Admin | 28,036 | 44,819 | 197,435 | 343,560 | 55,945 |
Research & Development | 8,484 | 10,837 | 16,081 | 7,316 | 4,894 |
Amortization of Goodwill & Intangibles | 179.74 | 228.15 | 248.5 | 246.23 | 230.14 |
Other Operating Expenses | 113.97 | 103.17 | 133.52 | 93.09 | 82.15 |
Operating Expenses | 39,426 | 65,867 | 147,956 | 351,137 | 136,296 |
Operating Income | -64,193 | -12,602 | 21,922 | 468,238 | 259,669 |
Interest Expense | -2,320 | -3,470 | -3,711 | -6,233 | -3,350 |
Interest & Investment Income | 13,455 | 14,593 | 14,433 | 5,710 | 211.98 |
Currency Exchange Gain (Loss) | 328.97 | -1,403 | -198.98 | -169.12 | -546.48 |
Other Non Operating Income (Expenses) | -495.13 | 8,837 | -41,370 | -7,750 | 757.1 |
EBT Excluding Unusual Items | -53,224 | 5,954 | -8,926 | 459,796 | 256,742 |
Gain (Loss) on Sale of Investments | -6,021 | -4,707 | 1,080 | 12.79 | - |
Gain (Loss) on Sale of Assets | -123.51 | -3.16 | -0.89 | -41.39 | 18.46 |
Asset Writedown | -46,013 | -1,389 | 1,967 | -1.1 | - |
Other Unusual Items | - | - | - | 3,929 | - |
Pretax Income | -105,381 | -143.86 | -5,879 | 463,696 | 256,760 |
Income Tax Expense | -22,308 | 936 | -580.48 | 113,951 | 66,683 |
Earnings From Continuing Operations | -83,073 | -1,080 | -5,299 | 349,746 | 190,077 |
Minority Interest in Earnings | 954.37 | 732.29 | 2,126 | -3,075 | -387.22 |
Net Income | -82,118 | -347.58 | -3,173 | 346,670 | 189,690 |
Net Income to Common | -82,118 | -347.58 | -3,173 | 346,670 | 189,690 |
Net Income Growth | - | - | - | 82.76% | 292.96% |
Shares Outstanding (Basic) | 35 | 25 | 34 | 34 | 36 |
Shares Outstanding (Diluted) | 35 | 25 | 34 | 38 | 37 |
Shares Change (YoY) | 41.84% | -26.52% | -10.73% | 1.46% | 7.75% |
EPS (Basic) | -2332.00 | -14.00 | -93.91 | 10050.42 | 5328.07 |
EPS (Diluted) | -2332.00 | -14.00 | -93.91 | 9212.00 | 5127.00 |
EPS Growth | - | - | - | 79.68% | 268.32% |
Free Cash Flow | -30,974 | 17,853 | -122,498 | 350,444 | 129,398 |
Free Cash Flow Per Share | -879.62 | 719.10 | -3625.74 | 9259.21 | 3468.64 |
Gross Margin | -79.24% | 47.36% | 48.73% | 79.25% | 78.39% |
Operating Margin | -205.39% | -11.21% | 6.29% | 45.29% | 51.41% |
Profit Margin | -262.74% | -0.31% | -0.91% | 33.53% | 37.55% |
Free Cash Flow Margin | -99.10% | 15.88% | -35.14% | 33.90% | 25.62% |
EBITDA | -47,034 | 7,476 | 37,882 | 479,065 | 265,733 |
EBITDA Margin | -150.48% | 6.65% | 10.87% | 46.34% | 52.61% |
D&A For EBITDA | 17,160 | 20,078 | 15,960 | 10,826 | 6,064 |
EBIT | -64,193 | -12,602 | 21,922 | 468,238 | 259,669 |
EBIT Margin | -205.39% | -11.21% | 6.29% | 45.29% | 51.41% |
Effective Tax Rate | - | - | - | 24.57% | 25.97% |
Advertising Expenses | 1,240 | 722.23 | 678.33 | 1,523 | 1,113 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.